Real-World Comparative Effectiveness of Donanemab Plus Usual Care Versus Usual Care Alone in US Patients with Early Symptomatic Alzheimer’s Disease

Clinical Trial Information

Trial Contact: Carlo, Charlene S, Colon Morales, Veronica J, Mondragon, Diana

IRB No: RNE

Principal Investigator: Mohiuddin, Yasmin

Phase: N/A

Age Group: Adult

ClinicalTrials.gov ID: NCT 06566170

Objective

To compare the effect of donanemab and Usual Care versus Usual Care alone on dependence level in participants with early symptomatic AD

Share: